Leadership in next generation biologics


Ambrx Technology Video


Ambrx is harnessing the power of introducing non-native amino acids through an expanded genetic code to both generate novel bio-therapeutics and to optimize the performance of bio-conjugated peptides, therapeutic proteins, monoclonal antibodies (mAbs) and bi- and multi-specific medicines.

Our technology platforms combine the power of conventional medicinal chemistry with cutting edge recombinant DNA-based protein biosynthesis. It allows us to incorporate non-native amino acids at selected sites in natural proteins as they are being made within the cells. These amino acids bear selectively linkable and (bioorthogonal) chemical groups that enable the precise and site-specific modification of therapeutic peptides, proteins, mAbs and mAb fragments. This approach, novel in the field, allows us to impart new functionality and empower the properties of cutting-edge biotech drugs.

We have engineered into the cell lines new tRNA/tRNA synthetase pairs (Orthogonal Sets)  that specifically recognize and incorporate non-natural amino acids at positions we define in the therapeutic proteins. These amino acids can be specifically chemically modified, allowing us to add functionality and empower the protein.  Our protein engineers, working side-by-side with functional biologists, are able to survey the surface of proteins, optimize the site of attachment and create protein conjugates with enhanced therapeutic activity. This Protein Medicinal Chemistry can be performed on any therapeutic protein or antibody using one of our proprietary bacterial (ReCODE), or yeast and mammalian (EuCODE) expression systems. We use ReCODE to create long acting therapeutic peptides and proteins and modified antibody and bi-specific fragments. We use EuCODE to create both larger and more complex proteins where the function may be critically dependent on the appropriate post-translational modification. Through these technology platforms, Ambrx has the potential to create best in class bio-conjugates by creating site-specific and homogeneous bio-molecules where the drug has been optimized for position of conjugation, linker design and functional payloads.